205 related articles for article (PubMed ID: 15973716)
1. Mycophenolate mofetil combination therapy improves long-term outcomes after liver transplantation in patients with and without hepatitis C.
Wiesner RH; Shorr JS; Steffen BJ; Chu AH; Gordon RD; Lake JR
Liver Transpl; 2005 Jul; 11(7):750-759. PubMed ID: 15973716
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
[TBL] [Abstract][Full Text] [Related]
4. A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C.
Klintmalm GB; Davis GL; Teperman L; Netto GJ; Washburn K; Rudich SM; Pomfret EA; Vargas HE; Brown R; Eckhoff D; Pruett TL; Roberts J; Mulligan DC; Charlton MR; Heffron TG; Ham JM; Douglas DD; Sher L; Baliga PK; Kinkhabwala M; Koneru B; Abecassis M; Millis M; Jennings LW; Fasola CG
Liver Transpl; 2011 Dec; 17(12):1394-403. PubMed ID: 21850690
[TBL] [Abstract][Full Text] [Related]
5. Dose optimization of mycophenolate mofetil when administered with a low dose of tacrolimus in cadaveric renal transplant recipients.
Squifflet JP; Bäckman L; Claesson K; Dietl KH; Ekberg H; Forsythe JL; Kunzendorf U; Heemann U; Land W; Morales JM; Mühlbacher F; Talbot D; Taube D; Tyden G; van Hooff J; Schleibner S; Vanrenterghem Y;
Transplantation; 2001 Jul; 72(1):63-9. PubMed ID: 11468536
[TBL] [Abstract][Full Text] [Related]
6. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report.
Jain A; Kashyap R; Dodson F; Kramer D; Hamad I; Khan A; Eghestad B; Starzl TE; Fung JJ
Transplantation; 2001 Sep; 72(6):1091-7. PubMed ID: 11579306
[TBL] [Abstract][Full Text] [Related]
7. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report.
Jain AB; Hamad I; Rakela J; Dodson F; Kramer D; Demetris J; McMichael J; Starzl TE; Fung JJ
Transplantation; 1998 Nov; 66(10):1395-8. PubMed ID: 9846530
[TBL] [Abstract][Full Text] [Related]
8. Corticosteroid-free immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year interim results of the HCV-3 study.
Klintmalm GB; Washburn WK; Rudich SM; Heffron TG; Teperman LW; Fasola C; Eckhoff DE; Netto GJ; Katz E
Liver Transpl; 2007 Nov; 13(11):1521-31. PubMed ID: 17969201
[TBL] [Abstract][Full Text] [Related]
9. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation.
Eckhoff DE; McGuire BM; Frenette LR; Contreras JL; Hudson SL; Bynon JS
Transplantation; 1998 Jan; 65(2):180-7. PubMed ID: 9458011
[TBL] [Abstract][Full Text] [Related]
11. New strategies using 'low-dose' mycophenolate mofetil to reduce acute rejection in patients following kidney transplantation.
Ulsh PJ; Yang HC; Holman MJ; Ahsan N
J Transpl Coord; 1999 Jun; 9(2):114-8. PubMed ID: 10703393
[TBL] [Abstract][Full Text] [Related]
12. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
[TBL] [Abstract][Full Text] [Related]
13. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
Becker T; Foltys D; Bilbao I; D'Amico D; Colledan M; Bernardos A; Beckebaum S; Isoniemi H; Pirenne J; Jaray J;
Transplantation; 2008 Dec; 86(12):1689-94. PubMed ID: 19104406
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
[TBL] [Abstract][Full Text] [Related]
15. Randomized, multicenter trial comparing tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-positive recipients of living donor liver transplantation.
Takada Y; Kaido T; Asonuma K; Sakurai H; Kubo S; Kiuchi T; Inomata Y; Isaji S; Tsumura H; Teramukai S; Matsubara Y; Sakabayashi S; Uemoto S
Liver Transpl; 2013 Aug; 19(8):896-906. PubMed ID: 23696054
[TBL] [Abstract][Full Text] [Related]
16. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of immunosuppression monotherapy after liver transplantation: a meta-analysis.
Lan X; Liu MG; Chen HX; Liu HM; Zeng W; Wei D; Chen P
World J Gastroenterol; 2014 Sep; 20(34):12330-40. PubMed ID: 25232269
[TBL] [Abstract][Full Text] [Related]
18. Initial steroid-free immunosuppression after liver transplantation in recipients with hepatitis C virus related cirrhosis.
Wietzke-Braun P; Braun F; Sattler B; Ramadori G; Ringe B
World J Gastroenterol; 2004 Aug; 10(15):2213-7. PubMed ID: 15259068
[TBL] [Abstract][Full Text] [Related]
19. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplant recipients given tacrolimus and daclizumab/thymoglobulin: one year follow-up.
Ciancio G; Burke GW; Gaynor JJ; Roth D; Sageshima J; Kupin W; Tueros L; Hanson L; Rosen A; Ruiz P; Miller J
Transplantation; 2008 Jul; 86(1):67-74. PubMed ID: 18622280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
